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Relapses in multiple sclerosis (MS) are disruptive and frequently disabling for patients,
and their treatment is often a challenge to clinicians. Despite progress in the understand-
ing of the pathophysiology of MS and development of new treatments for long-term
management of MS, options for treating relapses have not changed substantially over
the past few decades. Corticosteroids, a component of the hypothalamic-pituitary-adrenal
axis that modulate immune responses and reduce inflammation, are currently the main-
stay of relapse treatment. Adrenocorticotropic hormone (ACTH) gel is another treatment
option. Although it has long been assumed that the efficacy of ACTH in treating relapses
depends on the peptide’s ability to increase endogenous corticosteroid production, evi-
dence from research on the melanocortin system suggests that steroidogenesis may only
partly account for ACTH influences. Indeed, the melanocortin peptides [ACTH and α-, β-,
γ-melanocyte-stimulating hormones (MSH)] and their receptors (Melanocortin receptors,
MCRs) exert multiple actions, including modulation of inflammatory and immune mediator
production. MCRs are widely distributed within the central nervous system and in periph-
eral tissues including immune cells (e.g., macrophages).This suggests that the mechanism
of action of ACTH includes not only steroid-mediated indirect effects, but also direct anti-
inflammatory and immune-modulating actions via the melanocortin system. An increased
understanding of the role of the melanocortin system, particularly ACTH, in the immune and
inflammatory processes underlying relapses may help to improve relapse management.
Keywords: multiple sclerosis, melanocortins, adrenocorticotropic hormone, anti-inflammatory, immune modula-
tion, MS relapses, corticosteroids
INTRODUCTION
Relapsing-remitting multiple sclerosis (RRMS) is the most com-
mon subtype of MS, accounting for over 80% of initial MS
diagnoses. Patients experience relapses (also called attacks or exac-
erbations or flare-ups), separated by periods of full or partial
recovery (Lublin and Reingold, 1996; Confavreux et al., 2000).
Relapses may lead to the accumulation of disability, and patients
usually do not return to their baseline (Lublin et al., 2003).
Although relapses are common and represent a defining feature
of MS, there remain gaps in our understanding of their clinical
management.
Over the last decade, the mainstay of treatment for relapses
has been high-dose corticosteroids (National Clinical Advisory
Board of the National Multiple Sclerosis Society, 2008). Corti-
costeroid treatment shortens the time to recovery from relapses
(Filippini et al., 2000; Burton et al., 2009), presumably due at
least in part to their anti-inflammatory effects. However, corti-
costeroids are not the sole option for the treatment of relapses.
Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar® Gel,
2011), a long-acting formulation of the full sequence ACTH(1–39)
that includes other pro-opiomelanocortin (POMC) peptides, is
considered an alternative to steroids in treatment of optic neuritis
and acute exacerbations of MS, as well as other conditions (H.P.
Acthar® Gel, 2011). Before recognition of melanocortin receptors
(MCR), ACTH effects were believed to depend on induction of
endogenous corticosteroid production (National Clinical Advi-
sory Board of the National Multiple Sclerosis Society, 2008; Sibley,
2009). However, recent evidence suggests that ACTH has addi-
tional actions independent of those related to endogenous steroid
production. For example, ACTH has been shown to be effective in
the treatment of infantile spasms (IS), a condition in which corti-
costeroid treatment has limited effectiveness (Baram et al., 1996;
Mackay et al., 2004; Stafstrom et al., 2011). Relevant to MS, emerg-
ing evidence indicates that ACTH exerts direct anti-inflammatory
and immune-modulating effects within the central nervous system
(CNS) and in peripheral tissues, and that these effects are mediated
via the melanocortin receptors (Catania et al., 2004, 2010).
The objectives of this review are (1) to provide an overview of
relapses, (2) to review the pathophysiology of MS with a focus on
relapses, (3) to summarize current methods of relapse manage-
ment, (4) to explore the actions of ACTH via the melanocortin
system, and (5) to discuss the relevance of the melanocortin sys-
tem to MS. These topics are addressed and discussed in the context
of our collective clinical experience.
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OVERVIEW OF RELAPSES
A relapse can be defined as an acute or insidious onset of new
or worsening MS symptoms that are directly related to the dis-
ease and not attributed to environmental or systemic triggers,
lasting for at least 24 h. Paroxysmal symptoms may be consid-
ered relapses if they consist of multiple episodes occurring over
24 h (Polman et al., 2011). Relapses vary in presentation and may
include motor or sensory symptoms which may reflect the loca-
tion of the demyelinating event and inflammation (Vollmer, 2007;
Compston and Coles, 2008). The changes attributable to a relapse
can persist for several weeks to months (Vollmer, 2007), although
the time to recovery may be shortened with treatment (Filippini
et al., 2000).
In clinical practice, the diagnosis and treatment of relapses
may present many challenges. There are several types of relapses
(e.g., optic neuritis, brainstem, myelitis), and even within each
type of relapse, symptoms can vary (Frohman et al., 2008). Iden-
tifying relapses and ruling out pseudo-relapses in the presence
of infection may be difficult (Vollmer, 2007; Thrower, 2009).
Distinguishing between relapses and steady progression requires
careful consideration, clinical skills, and judgment as the clinical
manifestations of relapses as well as progressive symptoms can
be quite similar (Frohman et al., 2008). Symptom presentation
may provide clues for the clinician. For example, neuropathic
pain such as tingling/pins-and-needle sensations may indicate a
relapse (myelitis) if it is acute and/or transient, whereas chronic
or insidious sensory changes or pain syndromes more likely
reflect disease progression. Similarly, new onset sudden weak-
ness of both legs affecting the ability to walk suggests a relapse
whereas gradual change in walking ability over a long period
of time suggests disease progression. Furthermore, treatment
of relapses presents another challenge. Although short courses
of high-dose corticosteroids are widely used and are generally
accepted as the primary treatment option, for some patients
there are limitations in terms of effectiveness, tolerability, and
satisfaction with treatment outcomes (Nickerson and Marrie,
2011).
PATHOPHYSIOLOGY OF MS
Multiple sclerosis is an immune-mediated disease leading to CNS
inflammation, demyelination, and degeneration (Frohman et al.,
2008; Boppana et al., 2011). Acute inflammatory demyelination
and axonal loss in focal lesions are believed to be responsible
for clinical manifestations of relapses (Noseworthy et al., 2000;
Bruck, 2005a; Frohman et al., 2008). Chronic demyelination,
axonal loss, and gliosis (i.e., a proliferation of astrocytes in dam-
aged areas of the CNS, which usually leads to the formation of
a glial scar) are associated, although not exclusively, with pro-
gressive MS, and are believed to contribute to chronic neurologic
deficits (Bruck, 2005b; Frohman et al., 2005). Neurodegenerative
effects associated with disease progression may be associated with
inflammation and lesion formation (Frischer et al., 2009), how-
ever there may be processes that contribute to axonal loss separate
from those that cause demyelination (Trapp et al., 1998; Bruck,
2005a; DeLuca et al., 2006). The following discussion focuses
on acute demyelination and inflammatory processes relevant to
relapses.
DEMYELINATION AND INFLAMMATION
Myelin, which is formed by oligodendrocytes in the CNS,
surrounds and protects axons while functioning to facilitate
signal conduction along the axon. Myelin damage leads to
conduction slowing or completely blocked conduction, which
underlies the clinical presentation of relapses. Demyelination
involves several types of immune cells (e.g., T cells, B cells,
and macrophages/monocytes) and inflammatory mediators (e.g.,
cytokines and chemokines; reviewed by Frohman et al., 2008; Bop-
pana et al., 2011). Various contributors to CNS inflammation and
demyelination are illustrated in Figure 1, and outlined below.
Increased blood-brain barrier (BBB) permeability is a hallmark
of MS and is a key factor in the inflammatory process leading
to demyelination and formation of MS lesions (Boppana et al.,
2011). Immune and inflammatory cells that are activated in the
periphery, possibly by myelin antigen(s) or microbial antigens
cross-reactive with myelin, can increase BBB permeability, thereby
allowing infiltration of proinflammatory cells (e.g., T cells and B
cells) into the CNS. Penetration of immune cells into the CNS
is promoted by enhanced expression of adhesion molecules and
release of chemokines (e.g., CCL2, CCL5, CXCL1, CXCL2; Wilson
et al., 2010) provide an informative summary) and substances like
mixed metalloproteinases (MMPs) that promote the migration
of immune cells and contribute to disruption of the BBB (Prat
et al., 2002; Correale and Villa, 2007). From a clinical perspective,
the appearance of gadolinium-enhancing MS lesions on magnetic
resonance imaging is due to the permeability of the compromised
integrity of the BBB; that is, gadolinium can only enter the CNS
if the BBB is disrupted. The gadolinium “stains” the lesion in the
CNS and presents it as an acute lesion that may correlate with
the patients’ symptoms; however some Gd+ lesions are clinically
silent unless they are large or involve eloquent areas of the CNS,
e.g., an enhancing lesion in the brain stem.
T cells have a key role in MS (reviewed in Fletcher et al.,
2010). CD4+ T helper cells (i.e., Th1, Th2, and Th17 cells) and
CD8+ T cells have been shown to be present in MS lesions
(Lassmann et al., 2007) and are implicated in the pathogenesis
of MS (Mars et al., 2011). T cells in the CNS become activated
(or re-activated) upon presentation of a myelin antigen, leading
to secretion of cytokines and inflammatory mediators (Fletcher
et al., 2010). Specifically, Th1 cells release the proinflammatory
cytokines IFN-γ and tumor necrosis factor-α (TNF-α), which have
several functions, including activation of macrophages (Boppana
et al., 2011). Th17 cells produce interleukin (IL)-17A, IL-17F, IL-21,
and IL-22, a key inflammatory mediator (Boppana et al., 2011).
Regulatory T cells (Treg) normally control the intensity of the
immune response and maintain self-tolerance through produc-
tion of anti-inflammatory cytokines, such as IL-10 (Frohman et al.,
2008; Awad and Stuve, 2010; Boppana et al., 2011). In addition,
CD4+ Th2 cells produce IL-4, IL-5, and IL-13, that can inhibit
macrophage function (Frohman et al., 2008; Awad and Stuve,
2010). There appears to be a dysregulation in levels or impair-
ment of functioning of regulatory/anti-inflammatory T cells in MS
(Costantino et al., 2008; Frohman et al., 2008; Correale and Villa,
2010; Mikulkova et al., 2011). Treg reduction and dysfunction may
be greater in RRMS compared with progressive MS (Venken et al.,
2006). Further, this dysregulation may be particularly relevant to
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FIGURE 1 | Cells and inflammatory mediators involved in demyelination.
relapses, as suggested by evidence of decreased Treg cells (Cor-
reale and Villa, 2010), as well as imbalances of proinflamma-
tory and anti-inflammatory/regulatory cytokines during relapses
(Hollifield et al., 2003).
B cells also appear to have a role in MS and demyelination
(reviewed in Frohman et al., 2008; Berer et al., 2011; Boppana et al.,
2011) as data have shown that B cells in the cerebrospinal fluid
(CSF) correlate with early CNS inflammation in RRMS (Kuenz
et al., 2008). B cells generate antibodies against myelin that activate
the complement cascade, leading to opsonization (phagocyto-
sis/destruction) of myelin and oligodendrocytes (Bruck, 2005a).
Further, certain B cell subtypes (memory B cells) contribute to
proinflammatory cytokine production (e.g., lymphotoxin and
TNF-α; Duddy et al., 2007) and may act as antigen-presenting
cells to activate T cell differentiation (Racke, 2008; Weber et al.,
2010; Wootla et al., 2011). For example, a study of treatment naïve
patients with RRMS demonstrated that memory B cells stimulated
CD4+ T cell proliferation in response to neuro-antigens [myelin
basic protein and myelin oligodendrocyte glycoprotein (MOG),
a membrane protein expressed on oligodendrocytes; Harp et al.,
2010]. Some B cells, however, can exert anti-inflammatory effects
through production of regulatory cytokines (e.g., IL-10) and
facilitating Treg cell development (Duddy et al., 2007; Weber and
Hemmer, 2010).
Macrophages and microglia are also implicated in the processes
of inflammation and acute demyelination. Activated macrophages
can damage myelin and oligodendrocytes through phagocytosis,
which may be mediated via T cells or antibodies and complement
(via B cells; Bruck, 2005a; Breij et al., 2008; Gandhi et al., 2010).
Macrophages and activated microglia also release cytotoxic sub-
stances, such as nitric oxide (NO) and reactive oxygen species,
which contribute to myelin damage (Glass et al., 2010) as well as
cytokines and other inflammatory mediators (Hauser and Oksen-
berg, 2006; Gandhi et al., 2010). Macrophages and microglia can
act as antigen-presenting cells, which present the antigen to naïve T
lymphocytes and produce cytokines that stimulate differentiation
of T cells into effector cells, which are responsible for executing
immune functions (such as Th1, Th2, Th17, Treg, and others; Glass
et al., 2010). Microglia can also present antigen to primed T cells,
re-stimulating them to release inflammatory cytokines (Carson,
2002). In turn, activated T cells and cytokines, such as IFN-γ, can
activate macrophages and microglia, which then release additional
proinflammatory cytokines and chemokines (Sorensen et al., 1999;
Carson, 2002; Boppana et al., 2011).
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Remyelination following resolution of the acute inflamma-
tory process is believed to contribute to recovery following
a clinical relapse. However, remyelination is often incomplete
(Bruck, 2005a), as oligodendrocytes are damaged by inflamma-
tory processes (Chandran et al., 2008). Astrocytes proliferate and
become hypertrophic in new lesions (Frohman et al., 2005) and
form glial scars in areas where axonal transection has occurred
(Frohman et al., 2008), which can be seen in chronic lesions
(Frohman et al., 2006). Astroglial scarring impairs remyelination
and repair (Carson et al., 2006; Frohman et al., 2006; Nair et al.,
2008). Incomplete remyelination may contribute to the residual
disability experienced by patients following resolution of a relapse;
this disability may be primarily due to decreased conduction and
damaged axons.
NEURODEGENERATIVE PROCESSES
Neurodegenerative processes related to relapsing and progressive
disease have not been fully elucidated. Although axonal damage
has been demonstrated early in the course of MS, cumulative
axonal damage over time appears to be an important contribu-
tor to clinical progression and sustained disability (Frohman et al.,
2005; Petzold et al., 2005). Several potential mechanisms may be
involved.
Axonal damage is seen early in MS lesion formation, suggesting
that it may occur as a result of acute inflammatory demyelinat-
ing events (Bitsch et al., 2000; Bruck, 2005a). Multiple mediators
of the immune response associated with acute inflammation and
demyelination, including T cells, B cells, macrophages, cytokines,
antibodies, NO, glutamate, and MMPs contribute to axon injury
(Bruck, 2005a; Frohman et al., 2005). Accumulation of damage
resulting from recurrent demyelinating events may account for
some degree of axonal loss and disease progression.
Axonal injury may also develop independently of inflamma-
tory demyelination (De Stefano et al., 2002). Although axonal
injury/transection is most prominent in active demyelinating
lesions (Trapp et al., 1998; Bruck, 2005b), acute axonal damage
also occurs in partially remyelinating lesions and inactive demyeli-
nated lesions (Bitsch et al., 2000). Cortical lesions (gray matter)
show signs of neuronal loss (Hauser and Oksenberg, 2006), even
though infiltration of inflammatory cells is lesser compared with
white matter plaques (Bruck, 2005b). Further, axonal loss can
occur without demyelination, as demonstrated by a study that
showed injured axons with intact myelin (Bjartmar et al., 2001).
Axonal damage in normal-appearing white matter may be due, in
part, to Wallerian degeneration, which means damage distally to
the injured plaques (Carson, 2002; Casanova et al., 2003; Bruck,
2005b; Lassmann, 2007). In patients with RRMS, the degree of
axonal damage in normal-appearing white matter is significantly
correlated with disability, suggesting that diffuse axonal damage
outside of lesions may contribute substantially to chronic disabil-
ity (Fu et al., 1998). Diffuse axonal injury in normal-appearing
white matter is more pronounced in progressive MS compared
with RRMS. This widespread injury is associated with a mild, but
diffuse, inflammatory reaction, and extensive microglial activation
(Kutzelnigg et al., 2005).
Finally, it has been suggested that chronically demyelinated
axons may degenerate due to impaired regeneration potential or
lack of trophic support from myelin and oligodendrocytes (Bruck,
2005b; Frohman et al., 2005). As noted previously, astroglial scar
formation can impede regeneration (some evidence of axon regen-
eration has been observed in mouse models) and repair (Carson
et al., 2006; Nair et al., 2008).
THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS
The hypothalamic-pituitary-adrenal (HPA) axis feedback loop is
illustrated in Figure 2 (Jacobson, 2005; Papadimitriou and Priftis,
2009). In response to stress or injury, the hypothalamus releases
corticotropin-releasing hormone (CRH), which stimulates the
anterior pituitary gland to release ACTH. ACTH stimulates the
adrenal cortex to secrete cortisol. Excess cortisol acts in a negative
feedback loop to inhibit CRH and ACTH secretion by the hypo-
thalamus and the anterior pituitary gland, respectively (Jacobson,
2005; Papadimitriou and Priftis, 2009).
Hypothalamic-pituitary-adrenal axis regulates many processes,
including aspects of the immune response. The neuroendocrine
and immune systems communicate bidirectionally (Chrousos,
1995; Haddad et al., 2002). Notably, cytokines, including several of
those involved in the inflammatory processes previously described
(e.g., TNF-α, IL-1), have a role in HPA axis regulation (Chrousos,
1995; Turnbull and Rivier, 1999; Haddad et al., 2002).
Some evidence shows that HPA axis function is dysregulated in
patients with MS (Huitinga et al., 2003, 2004; Ysrraelit et al., 2008),
although other data indicate normal HPA axis function (Limone
et al., 2002). In addition to HPA axis hyperactivity (Ysrraelit et al.,
2008) and chronic HPA activation (Huitinga et al., 2003), studies
have also demonstrated impaired glucocorticoid receptor binding
in lymphocytes (Then Bergh et al., 1999a; Ysrraelit et al., 2008),
which may be a contributing factor to the suboptimal response in
some patients to steroid treatment for relapses. Increased activ-
ity of HPA axis is also associated with fatigue (Gottschalk et al.,
2005) and cognitive impairment (Heesen et al., 2002), which are
FIGURE 2 | Hypothalamic-pituitary-adrenal axis. ACTH,
adrenocorticotropic hormone; CRH, corticotropin-releasing hormone.
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commonly reported by patients experiencing relapses. The extent
of HPA axis hyperactivity is associated with the clinical type of MS
(Then Bergh et al., 1999b), and may be a predictor of progression
(Gold et al., 2005a). Finally, neurodegeneration has been linked
to HPA axis hyperactivity (Gold et al., 2005b; Gold and Heesen,
2006).
CURRENT METHODS OF RELAPSE MANAGEMENT
Approaches to relapse management vary widely, depending on
number of factors such as the severity of relapse symptoms, patient
or clinician preference, costs, and convenience. Some clinicians
may choose not to actively treat relapses with mild or sensory
symptoms that do not impair a patient’s daily functioning. For
relapses that require treatment, options include high-dose corti-
costeroids, ACTH gel, plasmapheresis/plasma exchange (PLEX),
and intravenous immunoglobulins (IVIG; Elovaara et al., 2008;
National Clinical Advisory Board of the National Multiple Scle-
rosis Society, 2008; Cortese et al., 2011; H.P. Acthar® Gel, 2011).
High-dose corticosteroids are the standard of care for treating
relapses; anti-inflammatory mechanisms and clinical use (dosing
and side effects) are summarized below. ACTH gel may present
an appropriate alternative to high-dose corticosteroid for some
patients; its clinical use is summarized below and potential mech-
anisms of action (MOA) are explored later. PLEX is generally
reserved for treatment of relapses that are severe or refractory
to treatment with high-dose corticosteroids or ACTH, as evidence
of its clinical efficacy is limited (Cortese et al., 2011). IVIG is
sometimes used in patients for whom high-dose corticosteroids
are contraindicated or not tolerated, but there is not consistent
evidence for its use in relapse management (Elovaara et al., 2008).
PLEX and IVIG are not discussed in detail.
As noted earlier, high-dose corticosteroids are the most com-
mon treatment for relapses. The efficacy of high-dose corticos-
teroids in speeding recovery from MS relapses has been demon-
strated in several studies (Filippini et al., 2000). High-dose cor-
ticosteroids suppress the immunologic activation associated with
MS relapses via several mechanisms (Sloka and Stefanelli, 2005).
For example, methylprednisolone inhibits activation of T cells,
decreases the influx of immune cells into the CNS, may facili-
tate apoptosis of activated immune cells, reduces production of
inflammatory cytokines and indirectly decreases their cytotoxic
effects, and reduces expression of several target genes related to
inflammatory processes (Wandinger et al., 1998; Airla et al., 2004;
Sloka and Stefanelli, 2005; Elovaara et al., 2006). Pulse therapy with
intravenous methylprednisolone (IVMP) in patients with RRMS
or progressive forms of MS may delay brain atrophy, slow progres-
sion of disability (Zivadinov et al., 2001), reduce T2 lesion volume
(Then Bergh et al., 2006), and prevent confluence and enlargement
of lesions (Zivadinov et al., 2008).
Common high-dose corticosteroid treatment regimens for
relapses include IVMP (1 g/day for 3–5 days) or oral pred-
nisone (1000–1250 mg/day for 5 days; National Clinical Advisory
Board of the National Multiple Sclerosis Society, 2008; Mor-
row et al., 2009). Oral administration may offer greater conve-
nience and ease of use for patients. Adverse events associated
with high-dose corticosteroids include infection, hyperglycemia,
mood effects (euphoria, psychosis), gastrointestinal symptoms,
taste disturbances, insomnia, weight gain, edema, and hyperten-
sion; potential long-term effects include osteoporosis, cataracts,
glaucoma, Cushingoid features, immune suppression, hyperna-
tremia, and hypokalemia; rarely, patients treated with corticos-
teroids may develop avascular necrosis (AVN) of major joints,
even after one dose of corticosteroid (Lyons et al., 1988; National
Clinical Advisory Board of the National Multiple Sclerosis Society,
2008).
Adrenocorticotropic hormone gel, as previously noted, may
be considered as an alternative treatment of MS relapses. In our
experience, reasons for using ACTH include a lack of benefit estab-
lished with corticosteroids, inability to tolerate corticosteroids or
adverse effects, and poor IV access. Its efficacy has been studied
in several published investigations, and treatment outcomes may
be comparable to those seen with corticosteroids (Filippini et al.,
2000).
Adrenocorticotropic hormone gel is usually given at a dose of
80 U daily for 5 days, administered subcutaneously (SQ) or intra-
muscularly (IM). The option of IM or SQ can be adjusted to
patients’ experience with injections (e.g., if a patient is on IM
interferon, ACTH gel can be prescribed as IM and if a patient
is on glatiramer acetate, ACTH gel can be prescribed as SQ), to
increase its ease of use for patients. The side effect profile of
ACTH is generally similar to that of corticosteroids (Filippini et al.,
2000), and includes fluid retention, alteration in glucose toler-
ance, elevation in blood pressure, behavioral and mood changes,
increased appetite, and weight gain (see also list above for poten-
tial effects related to steroidogenesis; H.P. Acthar® Gel, 2011);
ACTH may have milder effects on bone and less risk of AVN
(Zaidi et al., 2010). Before discovery of melanocortin receptors,
ACTH gel was believed to work entirely by stimulating endoge-
nous steroid production (National Clinical Advisory Board of the
National Multiple Sclerosis Society, 2008; Sibley, 2009). However,
existing and emerging evidence related to this system indicates
additional effects of ACTH that may be relevant in terms of the
MOA of ACTH gel for treatment of relapses.
OVERVIEW OF MELANOCORTIN SYSTEM
Melanocortins (MC) and their receptors (MCR) compose an
ancient regulatory system, in existence for 500 million years
(Heinig et al., 1995; Klovins et al., 2004; Takahashi and Kawauchi,
2006; Haitina et al., 2007; Catania, 2008), that exerts multiple influ-
ences on the host, including anti-inflammatory, immunomodula-
tory, and behavioral effects (Catania et al., 2004).
The MC are a peptide family that includes ACTH (or corti-
cotropin) and the melanotropinsα-,β-,γ-melanocyte-stimulating
hormone (α-,β-,γ-MSH). The MC are derived from the precursor
POMC, which is synthesized in the pituitary, the arcuate nucleus
of the hypothalamus, the solitary tract of the medulla, and several
peripheral tissues (Papadimitriou and Priftis, 2009). Cleavage of
POMC by prohormone convertases 1 and 2 (PC1 and PC2) in
the anterior pituitary leads to formation of ACTH, which can be
further cleaved to generate α-MSH (Figure 3; Adan and Gispen,
1997; Papadimitriou and Priftis, 2009). Full sequence ACTH com-
prises 39 amino acids [i.e., ACTH(1–39)], of which α-MSH(1–13)
shares the 1–13 amino acid sequence; all of the MC share an
invariant sequence of four amino acids (His-Phe-Arg-Trp), which
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FIGURE 3 | Melanocortin peptides. ACTH, adrenocorticotropic hormone; CLIP, corticotropin-like intermediate lobe peptide; MSH, melanocyte-stimulating
hormone.
contributes to some overlap in terms of receptor recognition and
function (Catania et al., 2004).
There are five MCR subtypes (MC1R–MC5R), that are
expressed in various tissues throughout the body (Gantz et al.,
1993; Fathi et al., 1995; Xia et al., 1995; Chhajlani, 1996; Suzuki
et al., 1996; Chen et al., 1997; Taherzadeh et al., 1999; Lindskog
et al., 2010; Zaidi et al., 2010). The MCRs differ in their affinity
for individual MC peptides (Catania et al., 2004; Brzoska et al.,
2008). Notably, ACTH is the only MC peptide that is recognized
by all MCRs and it is the only MC peptide recognized by the
MC2R receptor in the adrenal cortex. The steroidogenic effects
of ACTH are mediated via activation of these receptors (Catania
et al., 2004). MCR affinity, distribution, and principal functions
are summarized in Table 1. This discussion focuses on the effects
of ACTH on the MC system that are potentially relevant to its
therapeutic MOA; however, it should be noted that due to the
wide distribution of MCRs and broad effects on multiple systems,
ACTH may have additional actions that are relevant in terms of
potential for side effects. For a comprehensive review of MC, see
Catania et al. (2004) or Brzoska et al. (2008).
Of particular relevance to MS, several types of immune cells
express MCRs. For example, peripheral T helper cells and mono-
cytes express MC1R, MC2R, MC3R, and MC5R mRNA (Andersen
et al., 2005); MC1R, MC2R, and MC3R have also been shown on
B cells (Johnson et al., 2001; Cooper et al., 2005); and MC2R on
macrophages (Johnson et al., 2001).
FUNCTIONS OF MELANOCORTIN SYSTEM RELEVANT TO MS
Various anti-inflammatory/immunomodulatory functions are
mediated via the MC system (Luger and Brzoska, 2007), some of
which may be relevant to the pathophysiologic processes involved
in MS. These effects are seen with various cell types (e.g., T
cells and macrophages) and other pathways (e.g., sympathetic
nervous system signaling) involved in inflammatory processes
(or regulation of inflammatory processes) implicated in MS. For
example, MC peptides have been shown to act directly to reduce
production of cytotoxic molecules and inflammatory mediators
in activated microglia (murine cells Delgado et al., 1998); and
macrophages (human Taherzadeh et al., 1999); and to enhance
immunoregulatory functions of T cells (Taylor and Kitaichi, 2008).
MC peptides also exert indirect effects via potentiation of sym-
pathetic/adrenergic pathways (Gothert, 1984; Szabo et al., 1989;
Macaluso et al., 1994; Nankova et al., 1996; Ichiyama et al., 1999a;
Serova et al., 2008) and modulation of neurotransmitters (Pran-
zatelli, 1994). These and other effects are described in more detail
below.
It should be noted that much of the evidence for melanocortin
effects on immune function comes from in vitro studies and
studies of animal models or conditions other than MS. How-
ever, these functions comprise biologically conserved sequences
and pathways that are consistent across multiple species and
cell types; thus it is reasonable to expect that these results may
extrapolate to many types of inflammatory processes, includ-
ing those implicated in MS. Similarly, most evidence is based
on studies that used α-MSH; this melanocortin peptide is often
selected for use in studies because it does not stimulate MC2R
and therefore its effects are not related to stimulation of corti-
costeroid production. However, given the overlap in amino acid
sequences and MCR affinity, it would be expected that ACTH
would have similar effects. Finally, although evidence demon-
strates the efficacy of ACTH in speeding recovery from MS
relapses, the specific physiological changes induced by modula-
tion of the MC system activity in patients with MS have not yet
been studied.
IMPACT ON CELLS AND PROCESSES INVOLVED IN MS
Adrenocorticotropic hormone and other melanocortin peptides
reduce production of proinflammatory cytokines and chemokines
Frontiers in Neurology | Multiple Sclerosis and Neuroimmunology March 2013 | Volume 4 | Article 21 | 6
Ross et al. Multiple sclerosis, relapses, and ACTH
Table 1 | MCR distribution, affinity, and functions.
MCR Ligand affinity Prevalent tissue Functions
MC1R α-MSH=ACTH>> γMSH Melanocytes Pigmentary effects; antipyretic/anti-inflammatory
Immune/inflammatory cells
Keratinocytes
Endothelial cells
Glial cells (CNS)
MC2R ACTH Adrenal cortex Steroidogenesis; bone formation(?)
Osteoblasts
MC3R γ-MSH=ACTH≥ α-MSH CNS Autonomic functions; anti-inflammatory
Macrophages
MC4R α-MSH=ACTH>> γMSH CNS Control of feeding/energy; neuroprotection; Erectile activity
MC5R α-MSH≥ACTH> γMSH Exocrine glands Regulation of exocrine secretions; immunoregulatory functions
Lymphocytes (T and B cells)
ACTH, adrenocorticotropic hormone; CNS, central nervous system; MCR, melanocortin receptor; MSH, melanocyte-stimulating hormone.
Adapted from Catania et al. (2004) reprinted with permission.
(e.g., IL-1, IL-8, TNF-α) and other mediators of inflammatory
processes (e.g., NO, adhesion molecules; Mason and Van, 1989;
Chiao et al., 1996; Catania et al., 1998; Delgado et al., 1998; Böhm
et al., 1999, 2005; Taherzadeh et al., 1999; Scholzen et al., 2003;
Manna et al., 2006). For example, in a study using a murine cul-
tured cell line,α-MSH(1–13),α-MSH(11–13), and ACTH(1–24) inhib-
ited production of TNF-α, IL-6, and NO by activated microglia
(Delgado et al., 1998). Inhibition of TNF-α production by α-
MSH(1–13), ACTH(1–24), and ACTH(1–39) was also demonstrated
in human monocytes and macrophages (Taherzadeh et al., 1999).
In human neutrophils and macrophages,α-MSH inhibited several
IL-8-mediated functions, including chemotaxis, enzyme release,
and generation of reactive oxygen (Manna et al., 2006). This
is a momentous effect as IL-8 is a key mediator of inflam-
mation and is also involved in the development and progres-
sion of cancer (Waugh and Wilson, 2008). ACTH and MC may
also promote the anti-inflammatory processes. For example, α-
MSH increases expression of the anti-inflammatory cytokine IL-
10 mRNA in keratinocytes and induces production of IL-10 in
human monocytes (Bhardwaj et al., 1996; Redondo et al., 1998).
Thus, in MS, ACTH may act by modulating macrophage and
other cell activity and cytokine levels; the consequent reduc-
tion of central inflammation may protect myelin and axons from
destruction.
A key mechanism underlying the anti-inflammatory effects of
MC peptides appears to be the modulation of nuclear factor (NF)-
κB signaling (Manna and Aggarwal, 1998; Ichiyama et al., 1999b;
Scholzen et al., 2003). NF-κB is a transcription factor that regulates
expression of several genes involved in immune and inflammatory
processes (e.g., those that code for proinflammatory cytokines,
MMPs, adhesion molecules, and inflammatory enzymes), NF-κB
is retained in an inactive form in the cytoplasm, bound to mem-
bers of the IκB inhibitory protein family. Phosphorylation of IκB
by various agents such as cytokines, bacterial products, and viruses
causes IκB degradation. Subsequently, the free NF-κB is translo-
cated to the nucleus where it binds to sequences of DNA encoding
NF-κB-responsive elements and triggers the transcription of target
genes (Beg et al., 1993; Baldwin, 1996). Because NF-κB is found in
many cell types relevant to MS, inhibition of this factor could result
in regulation of inflammation via several avenues (Yan and Greer,
2008). In lymphocytes stimulated with lipopolysaccharide (LPS),
α-MSH reduced NF-κB activation, adhesion molecule expres-
sion, and adhesion molecule-mediated adhesion of lymphocytes
(Scholzen et al., 2003). LPS-induced TNF-α production in leuko-
cytes was likewise inhibited by α-MSH (Yoon et al., 2003). NF-κB
inhibition is achieved via MC modulation of cytokine activity,
as shown in a study demonstrating that α-MSH inhibited IL-8-
induced NF-κB activation in human macrophages (Manna et al.,
2006). In addition, parenteral administration of α-MSH inhibited
NF-κB activation in a murine model of experimental acute brain
inflammation (Ichiyama et al., 1999b). This finding is also relevant
for MS treatment as it suggests that MCs such as ACTH adminis-
tered peripherally, can exert significant anti-inflammatory effects
within the brain.
Adrenocorticotropic hormone and other MCs exert immunomod-
ulatory effects by affecting T cell functions. For example, in studies
on experimental autoimmune encephalomyelitis (EAE, a mouse
model for MS), orally administered ACTH induced expression
of Treg cells, increased secretion of immunoregulatory IL-4, and
decreased IL-17, IL-2, and IFN-γ in CNS lymphocytes (Brod and
Hood, 2011), while α-MSH induced T cells to produce regulatory
cytokines (Taylor and Kitaichi, 2008). In addition, studies of exper-
imental autoimmune uveitis have shown that α-MSH mediates the
induction of Treg cells and modulates T cell phenotype, essentially
converting primed T cells to act as Treg cells (Taylor and Namba,
2001; Namba et al., 2002). This effect appears to be mediated via
the MC5R on the primed T cells (Taylor and Namba, 2001). In MS,
decreasing the signaling of T helper cells may reduce recognition
of the self-antigen; likewise, increasing signaling of Treg cells may
help to control the number of autoimmune antigen-presenting
cells.
EFFECTS ON SYMPATHETIC NERVOUS SYSTEM AND
NEUROTRANSMITTERS
The role of the sympathetic nervous system in immune responses
and autoimmune diseases is demonstrated by the exacerbation
www.frontiersin.org March 2013 | Volume 4 | Article 21 | 7
Ross et al. Multiple sclerosis, relapses, and ACTH
of EAE following chemical ablation of the sympathetic ner-
vous system (Chelmicka-Schorr et al., 1988). Immune cells,
including lymphocytes, macrophages, and microglia, express β2-
adrenergic receptors (Schorr and Arnason, 1999), the activa-
tion of which leads to signals that help to control inflamma-
tion. This is illustrated by studies showing that β2-adrenergic
agonists inhibit macrophage functions, including reduced pro-
duction of TNF-α (Chelmicka-Schorr et al., 1988; Schorr and
Arnason, 1999). The observation that β2-adrenergic agonists sup-
press EAE (Wiegmann et al., 1995) suggests that the sympathetic
nervous system effects may be relevant to MS. Although β2-
adrenergic agonists are not routinely used in MS treatment, one
study found that add-on treatment with albuterol in MS patients
receiving glatiramer acetate was associated with improvement in
clinical outcomes, including relapse rates, and MS Functional
Composite (MSFC) scores at 6 and 12 months (Khoury et al.,
2010).
Adrenocorticotropic hormone and other MC can acti-
vate anti-inflammatory signals via potentiation of sympa-
thetic/adrenergic pathways (Gothert, 1984; Szabo et al., 1989;
Macaluso et al., 1994; Nankova et al., 1996; Ichiyama et al.,
1999a; Serova et al., 2008). For example, ACTH has been
shown to increase expression of tyrosine hydroxylase [an enzyme
involved in norepinephrine (NE) synthesis] mRNA in rat
brain (Nankova et al., 1996; Serova et al., 2008). Addition-
ally, centrally administered α-MSH potentiates peripheral beta-
adrenergic anti-inflammatory effects via descending neural path-
ways (Macaluso et al., 1994; Ichiyama et al., 1999a). Further,
MC peptides stimulate increased release of NE from periph-
eral sympathetic nerve endings (Gothert, 1984; Szabo et al.,
1989).
In addition to increasing synthesis of NE in the CNS (Nankova
et al., 1996; Serova et al., 2008),ACTH modulates synthesis, release,
and actions of other neurotransmitters, including dopamine
and acetylcholine, within the CNS (Pranzatelli, 1994). Recep-
tors for several of these neurotransmitters have been identified
on microglia and macrophages; engagement of these receptors
has inhibitory effects on microglia (Chang and Liu, 2000; Haskó
et al., 2002; Shytle et al., 2004; Färber et al., 2005). Poten-
tiation of neurotransmitter signaling in the brain by ACTH
or other MC may stimulate these inhibitory receptors, thereby
reducing microglial activation. As noted previously, microglia
are an important component of the inflammatory mechanisms
leading to demyelination and lesion formation in MS; (Car-
son, 2002; Boppana et al., 2011) thus, this may be one mech-
anism by which ACTH works in treating relapses. In addi-
tion, widespread microglial activation has been demonstrated
in secondary progressive MS (SPMS; Kutzelnigg et al., 2005),
suggesting that ACTH may be of benefit in the progressive
phase of MS; however, this has not been studied in clinical
trials.
One issue in considering the evidence described here in terms
of its applicability to clinical practice, is that many of the stud-
ies were performed in vitro or in animal models in which ACTH
or α-MSH was administered directly into the brain. This is in
contrast to the clinical situation in which ACTH is adminis-
tered peripherally (IM or SQ), which may raise the question of
whether ACTH gel can actually have effects on the CNS. However,
the permeability of the BBB is compromised in MS, particularly
during relapses (Kermode et al., 1990; Prat et al., 2002), which
would allow peripherally administered ACTH to pass through.
Further, because MC4Rs are expressed throughout the CNS and
on vagal sensory afferent nerves that project to the CNS (Gautron
et al., 2010), ACTH in the periphery can have central effects. In
fact, there is evidence demonstrating that systemic administra-
tion of ACTH affects behavior and neurotransmitters (Sandman
and Kastin, 1981; de Wied and Jolles, 1982; Serova et al., 2008).
Finally, from a clinical perspective, the efficacy of ACTH gel in
other conditions, such as IS, demonstrates its ability to affect the
brain, as it is a disease confined to the brain (Stafstrom et al.,
2011).
Thus, the clinical experience of effectiveness of ACTH gel in
cases of corticosteroid non-responsive patients treated for relapse
may be explained, at least in part, by the actions of ACTH via the
MC system.
EMERGING EVIDENCE AND FUTURE DIRECTIONS
Although it is beyond the scope of this review, additional research
endeavors have begun to examine other aspects of ACTH/MC
signaling that may be relevant to MS. For example, some evi-
dence suggests that vagal nerve involvement may play a role
in anti-inflammatory/immunomodulatory effects (Richman and
Arnason, 1979; Adan and Gispen, 1997; Kishi et al., 2003; Guarini
et al., 2004; Pavlov et al., 2006; Wan et al., 2008; Gautron et al.,
2010). Evidence suggesting neuroprotective effects of ACTH/MCs
(Strand and Kung, 1980; van der Neut et al., 1992; Catania, 2008),
raises the possibility for a role of ACTH gel in treatment of pro-
gressive forms of MS. Bone maintenance functions mediated via
the MC system (Zaidi et al., 2010) may be relevant in light of bone
loss related to immobility associated with MS, as well as the poten-
tial for bone loss related to side effects of corticosteroid or ACTH
treatment.
Future directions for additional research may include effects of
ACTH and other MC on cognition, as cognitive dysfunction is an
important aspect of MS. Investigations of MC functions related to
strength, mobility, and other functions would be of interest to the
MS community.
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